We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs (DECLARE)

This study has been terminated.
(Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00300573
First Posted: March 9, 2006
Last Update Posted: June 4, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Incyte Corporation
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2006
  Primary Completion Date: No date given